公开(公告)号：US20100135998A1

公开(公告)日：2010-06-03

申请号：US12527459

申请日：2008-02-26

申请人： Edward Paul Bowman ,  Daniel J. Cua ,  Robert A. Kastelein ,  Kathy Lynn Miller ,  Melanie A. Kleinschek ,  Kristian S. Bak-Jensen ,  Katia Boniface ,  Brent S. McKenzie ,  Rene de Waal Malefyt

发明人： Edward Paul Bowman ,  Daniel J. Cua ,  Robert A. Kastelein ,  Kathy Lynn Miller ,  Melanie A. Kleinschek ,  Kristian S. Bak-Jensen ,  Katia Boniface ,  Brent S. McKenzie ,  Rene de Waal Malefyt

IPC分类号： A61K39/395 ,  A61P7/12 ,  A61P35/04 ,  A61P1/00 ,  C12N5/02 ,  C12Q1/02

CPC分类号： A61K39/3955 ,  A61K31/55 ,  A61K31/5575 ,  A61K38/1793 ,  A61K39/395 ,  A61K45/06 ,  C07K16/244 ,  C07K2317/76 ,  A61K2300/00

摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.

摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。

公开(公告)号：US20120156699A1

公开(公告)日：2012-06-21

申请号：US13405024

申请日：2012-02-24

申请人： Edward P. Bowman ,  Daniel J. Cua ,  Robert A. Kastelein ,  Kathy Lynn Miller ,  Melanie A. Kleinschek ,  Katia Boniface ,  Kristian S. Bak-Jensen ,  Brent S. McKenzie ,  Rene de Waal Malefyt

发明人： Edward P. Bowman ,  Daniel J. Cua ,  Robert A. Kastelein ,  Kathy Lynn Miller ,  Melanie A. Kleinschek ,  Katia Boniface ,  Kristian S. Bak-Jensen ,  Brent S. McKenzie ,  Rene de Waal Malefyt

IPC分类号： G01N33/566 ,  C07K16/46

CPC分类号： A61K39/3955 ,  A61K31/55 ,  A61K31/5575 ,  A61K38/1793 ,  A61K39/395 ,  A61K45/06 ,  C07K16/244 ,  C07K2317/76 ,  A61K2300/00

摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.

摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。